Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3609-3615

  Hoppe, Bernd ^a   Groothoff, Jaap W ^b   Hulton, Sally Anne ^c   Cochat, Pierre ^d   Niaudet, Patrick ^e   Kemper, Markus J ^f   Deschênes, George ^g   Unwin, Robert ^h   Milliner, Dawn ⁱ  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITÉ DE LYON   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ MAYO CLINIC   (United States)

Author keywords

efficacy; Oxalobacter formigenes; primary hyperoxaluria; safety; treatment

Indexed keywords

CREATININE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; OXABACT; OXALIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MALE; MULTICENTER STUDY; NAUSEA; OXALOBACTER FORMIGENES; OXALOSIS 1; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URINE LEVEL; VOMITING;

ADMINISTRATION, ORAL; AGED; CREATININE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPEROXALURIA; HYPEROXALURIA, PRIMARY; KIDNEY CALCULI; KIDNEY FAILURE, CHRONIC; MALE; OXALATES; OXALOBACTER FORMIGENES; PROGNOSIS;

EID: 80051929167     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr107     Document Type: Article

References (32)

1. Danpure CJ. Molecular etiology of primary hyperoxaluria type I: New directions for treatment. Am J Nephrol 2005; 25: 303-310
2. Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol 2001; 12: 1986-1993
3. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009; 75: 1264-1271
4. Lieske J, Monico C, HolmesWet al. International registry for primary hyperoxaluria. Am J Nephrol 2005; 25: 290-296
5. Cregeen DP, Williams EL, Hulton S et al. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 2003; 22: 497-506
6. Belostotsky R, Seboun E, Idelson GH et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010; 87: 392-399
7. Cochat P, Deloraine A, Rotily M et al. Epidemiology of primary hyperoxaluria type I. Nephrol Dial Transplant 1995; 10: 3-7
8. Kopp N, Leumann E. Changing pattern of primary hyperoxaluria in Switzerland. Nephrol Dial Transplant 1995; 10: 2224-2227
9. van Woerden CS, Groothoff JW, Wanders RJ et al. Primary hyperoxaluria type 1 in the Netherlands: Prevalence and outcome. Nephron Dial Transplant 2003; 18: 273-279
10. Milliner D. Treatment of the primary hyperoxalurias: A new chapter. Kidney Int 2006; 70: 1198-2000
11. Toussant C. Pyridoxine-responsive PH1: Treatment. J Nephrol 1998; 11: 49-50
12. Monico CG, Rossetti S, Olson JB et al. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005; 67: 1704-1709
13. Milliner DS, Eickholt JT, Bergstralh EJ et al. Results of long term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994; 331: 1553-1558
14. Leumann E, Hoppe B, Neuhaus T et al. Efficacy of oral citrate administration in primary hyperoxaluria. Nephrol Dial Transplant 1995; 10: 14-16
15. Allison MJ, Dawson KA, MayberryWRet al. Oxalobacter formigenes gen. nov. sp. nov.: Oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 1985; 141: 1-7
16. Sidhu H, Yenatska L, Ogden SD et al. Natural colonization of children in the Ukraine with the intestinal bacterium, Oxalobacter formigenes, using a PCR-based detection system. Mol Diagn 1997; 2: 89-97
17. Sidhu H, Schmidt ME, Cornelius JG et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract dwelling bacterium Oxalobacter formigenes: Possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999; 10: S334
18. Kaufman DW, Kelly JP, Curhan GC et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008; 19: 1197-203
19. Hatch M, Cornelius J, AllisonMet al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69: 691-698
20. Hatch M, Freel R. Intestinal transport of an obdurate anion: Oxalate. Urol Res 2005; 33: 1-16
21. Grujic D, Salido EC, Shenoy BC et al. Hyperoxaluria is reduced and nephrocalcinosi prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol 2009; 29: 86-93
22. Hatch M, Gjymishka A, Salido EC et al. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of Primary Hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011; 300: G461-469
23. Hoppe B, Beck B, Gatter N et al. Oxalobacter formigenes: A potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006; 70: 1305-1311
24. Wilson DM, Liedtke RR. Modified enzyme-based colorimetric assay of urinary and plasma oxalate with improved sensitivity and no ascorbate interference: Reference values and sample handling procedures. Clini Chem 1991; 37: 1229-1235
25. Werness PG, Brown CM, Smith LH et al. EQUIL2: A BASIC computer program for the calculation of urinary saturation. J Urol 1985; 134: 1242-1244
26. Ladwig PM, Liedtke RR, Larson TS. Sensitive spectophorotmetric assay for plasma oxalate. Clini Chem 2005; 51: 2377-2380
27. Schwartz GJ, Haycock GB, Edelmann CM Jr et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-263
28. Levey AS, Coresh J, Greene T et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serumcreatinine values. Clin Chem 2007; 53: 766-772
29. Zarembski PM, Hodgkinson A. Some factors influencing the urinary excretion of oxalic acid in man. Clin Chim Acta 1969; 25: 1-10
30. Greenblatt DJ, Ransil BJ, Harmatz JS et al. Variability of 24 hour urinary ceratinine excretion by nornal subjects. J Clin Pharmacol 1976; 16: 321-328
31. Hellerstein S, Berenbom M, Alon US, Warady BA. Creatinine clearance following cimetidine for estimation of glomerular filtration rate. Pediatr Nephrol 1998; 12: 49-54
32. Hatch M, Freel RM. The roles and mechanisms of intestinal oxalate transport in oxalate homeostasis. Semin Nephrol 2008; 28: 143-151